Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
Comment on Shah and Ayala
Needles can get quite small or quite large
What do you think people underestimate most here: muscle loss, structure, or the exit plan
It also provides a faster onset of action compared to solid dosage forms, as the liquid does not need to be broken down in the stomach before the active ingredient can be absorbed